MedTrace Logo

Frovatriptan and Menstrual Migraine

NCT01114711 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2018-04-12

No results posted yet for this study

Summary

We are looking for women who suffer from menstrual migraine to participate in a 2-visit migraine brain imaging research study. Our goal is to see how the menstrual migraine brain's pain pathways function when the migraineur has been taking Frovatriptan. During the screening visit (Visit 1) participants will sign the informed consent form, complete questionnaires, meet with the study physician, and have QST (quantitative sensory testing: to determine your pain thresholds for a heat stimulus) performed. For Visit 2's MRI scan, subjects will be asked to lie very still while the scan is occurring. In some parts, they will not have to do anything, while in others they will be asked to rate pain and unpleasantness for brush and thermal stimuli. Participants are compensated for both visits.

Conditions

  • Frovatriptan
  • Menstrual Migraine

Sponsors & Collaborators

  • Endo Pharmaceuticals

    collaborator INDUSTRY

  • Mclean Hospital

    lead OTHER

Principal Investigators

  • David Borsook, MD, PhD · Mclean Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01114711 on ClinicalTrials.gov